Ritlecitinib
Ritlecitinib is an irreversible covalent inhibitor of JAK3 and the TEC family of kinases (including ITK, RLK, BTK, BMX, and TXK) that blocks signaling from multiple pro-inflammatory cytokines through the JAK3/STAT pathway and T-cell receptor signaling through the TEC kinase pathway. It is approved for the treatment of alopecia areata in adults and adolescents, and is under investigation in other immune-mediated inflammatory conditions.
Berat Molekul
285,3400 g/mol
LogP
2,10
TPSA
73,90 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Struktur 2D
Cite this structure
Embed this structure
SMILES
C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C
InChI
InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
Molecular Formula
C15H19N5O
HBD / HBA
2 / 4
Ikatan yang Dapat Dirotasi
3
Atom Berat
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Ritlecitinib is an irreversible covalent inhibitor of JAK3 and the TEC family of kinases (including ITK, RLK, BTK, BMX, and TXK) that blocks signaling from multiple pro-inflammatory cytokines through the JAK3/STAT pathway and T-cell receptor signaling through the TEC kinase pathway. It is approved for the treatment of alopecia areata in adults and adolescents, and is under investigation in other immune-mediated inflammatory conditions.
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Yes, Ritlecitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4085457. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 118115473. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ritlecitinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ritlecitinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ritlecitinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ritlecitinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ritlecitinib"></drugfyi-drug>